WeylChem Group is the fine and specialty chemicals platform of International Chemicals Investors Group. With eleven companies and around 1,700 employees in Europe and North America, we are a global leader in the custom manufacturing of fine chemicals and supply customers with a wide range of advanced intermediates. We read moreare also a major player in innovative care chemicals and act as an innovation partner to a broad range of industries. [website]

Wilmington PharmaTech is a full service CRO serving pharmaceutical and biotechnology companies in five major areas including 1) cGMP synthesis, 2) Salt and Polymorph Studies (to discover a suitable salt and crystal form), 3) FTE Research (process or medicinal chemistry performed either in the US or China), 4) Analytical Services (e.g. read moremethod development, method validation, trace analysis), and 5) Bulk Intermediate Synthesis (kgs to tons). Wilmington PharmaTech currently has two locations in Newark, Delaware (Delaware Technology Park and Pencader Corporate Center) with process research labs, solid state chemistry lab, analytical lab, and cGMP kilo labs. The company is also expanding its non-GMP bulk intermediate production in China. [website]

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the pharmaceutical and healthcare industry around the world to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, read moreWuXi AppTec's integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, and cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2022 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made, and every disease can be treated.